Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

  Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.5% in pre-market trading after the company reported Q3 results.

Regeneron Pharmaceuticals: Q3 Earnings Insights

Regeneron earnings and sales beat third-quarter views comfortably for the biotech giant. Shares rose slightly early Thursday.

Regeneron Earnings, Sales Beat; Biotech Giant Rises

Regeneron Pharmaceuticals Inc. shares rose 1.6% in premarket trade Thursday, after the drug company blew past estimates for the third quarter and said it has shared data from its Phase 2/3 COVID-19 vaccine candidate trial with regulators. Regeneron said it had net income of $842 million, or $7.39 a share, in the quarter, up from $670 million, or $5.86 a share, in the year-earlier period.

Regeneron blows past third-quarter earnings estimates and says has shared COVID-19 vaccine data with FDA

TARRYTOWN, N.Y., Nov. 5, 2020 /PRNewswire/ -- Third quarter 2020 revenues increased 32% to $2.29 billion versus third quarter 2019(4) Third quarter 2020 EYLEA® U.S. net sales increased 11% to $1.32 billion versus third quarter 2019 Third quarter 2020 Dupixent® global net sales(2), which...

Regeneron Reports Third Quarter 2020 Financial and Operating Results

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Regeneron (REGN) This Earnings Season?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Regeneron (REGN)

Gilead Sciences

Moderna

Novavax

The U.S. government has pulled out all the stops to develop a treatment for Covid-19. These biotech stocks are leading the race for a cure.

4 Top Biotech Stocks to Buy for Operation Warp Speed

Johnson & Johnson

If you want to invest in companies developing COVID-19 treatments or vaccines, these stand out from the crowd.

2 Lucrative Coronavirus Stocks to Buy Right Now

Last week, Biotech company Regeneron said that data from late-stage trials of its Covid-19 antibody cocktail indicates that the drug helps to significantly reduce the viral load and medical visits for ambulatory Covid-19 patients. The U.S. FDA is currently evaluating the therapy for a possible.

What's Happening With Regeneron Stock?

Eli Lilly

Eli Lilly and Regeneron offer investors an attractive risk-to-reward ratio.

2 Rock-Solid Coronavirus Treatment Stocks to Buy Right Now

General Motors

PayPal

QUALCOMM

Uber

This week is coming right after the biggest week of earnings season, and many major names have still yet to report.

GM, PayPal, Qualcomm, Regeneron, Uber and More Major Earnings Coming This Week

Here are the top five reasons to hold onto shares of this blue-chip biotech forever.

5 Reasons to Buy Regeneron Stock and Never Sell

REGN is developing an antibody cocktail called REGN-COV-2 for COVID-19. REGN-COV-2 has already produced impressive results in COVID-19 outpatients.

A Setback For Regeneron's Antibody Cocktail

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients. What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday.

Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

What's in the Cards for Regeneron's (REGN) Q3 Earnings?

TARRYTOWN, N.Y., Oct. 30, 2020 /PRNewswire/ -- The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2...

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

Shares of Regeneron Pharmaceuticals Inc. slumped 1.2% in morning trading Friday, after the biotechnology company said an independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 recommended that the patient trial be "modified," with the enrollment of some patients place on hold. REGN-COV2 was one of the treatments prescribed to President Trump after he tested positive for COVID-19.

Regeneron says IDMC recommends halt of some REGN-COV2 trial enrollment for safety risks

The FDA has accepted an application that could expand Libtayo's addressable patient population to include an important niche.

Regeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients

TARRYTOWN, N.Y., Oct. 29, 2020 /PRNewswire/ -- Regeneron has been consistently ranked #1 or 2 Top Employer for past 10 years Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company was once again ranked as the top company to work for by Science magazine in its...

Regeneron Once Again Earns #1 Ranking in Science Magazine's Top Biopharma Companies to Work For

Sanofi

European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent® (alirocumab)

Regeneron Pharmaceuticals late Wednesday posted positive clinical trials data on its Covid-19 treatment and Thursday said a lung cancer drug received FDA priority review. Regeneron stock rose.

Regeneron Posts Positive Data For Covid-19 Treatment; Lung Cancer Drug Advances

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) said Wednesday data from late-stage clinical trials is indicative that its antibody cocktail for COVID-19 both reduced viral load and need for medical attention. What Happened: The antibody therapy reduced COVID-19-related medical visits by 57% among non-hospitalized patients, according to a company statement.

Regeneron Says COVID-19 Antibody Cocktail Reduced Viral Load, Need For Medical Care In Late-Stage Trial

The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020.

Did Regeneron Just Revive Hopes About Beating COVID-19?

Data from 524 patients in a randomized, double-blind trial showed the antibody treatment “significantly reduced viral load” and patient medical visits,” Regeneron said.

Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA Authorization

Shares of Regeneron Pharmaceuticals Inc. rose more than 3% in the extended session Wednesday after the company said its experimental antibody cocktail "significantly reduced" novel-coronavirus levels and the need for "further medical attention," including hospitalizations and emergency-room visits, in more people enrolled in its ongoing late-stage trial. "We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors," Regeneron's President and Chief Scientific Officer George D.

News for Regeneron Pharmaceuticals Stock (REGN)